MicroRNA prognostic markers for immune checkpoint inhibitor success in urologic cancers - PubMed
2 days ago
- #microRNA
- #immune checkpoint inhibitors
- #urologic cancers
- Immune checkpoint inhibitors (ICIs) have transformed treatment for urologic cancers like bladder cancer, renal cell carcinoma (RCC), and prostate cancer.
- Heterogeneous patient responses to ICIs highlight the need for reliable prognostic biomarkers.
- MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression post-transcriptionally and play a key role in tumor immune regulation and cancer progression.
- This review focuses on miRNA prognostic markers that predict ICI success in urologic cancers, covering their biological functions, clinical utility, and therapeutic implications.
- Discusses miRNA signatures with prognostic value, their mechanisms in modulating immune checkpoints, and potential for personalized immunotherapy strategies.
- First comprehensive synthesis linking miRNA mechanisms, circulating biomarkers, and therapeutic modulation in urologic cancers with ICIs.